Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II booster and immune memory study of 10-valent pneumococcal conjugate vaccine versus Pneumovax 23 in previously primed children
2005-003052-36Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2005
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed), 23-valent pneumococcal polysaccharide vaccine and pertussis filamentous haemagglutinin in pneumococcal disease (2 arms), sponsored by GSK. Primary endpoint: Anti-pneumococcal antibody concentrations one month after vaccination. Started Aug 2005; status: completed.
02
Drugs
pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)23-valent pneumococcal polysaccharide vaccinepertussis filamentous haemagglutinin
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-003052-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003052-36.